Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kirchhoff

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Journal of Medicinal Chemistry|July 1, 2021
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor RegressionMeng Zhang, Angelo Aguilar, Shilin Xu, et al.
Journal of Medicinal Chemistry|June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate CancerXin Han, Lijie Zhao, Weiguo Xiang, et al.
Journal of Medicinal Chemistry|September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate CancerWeiguo Xiang, Lijie Zhao, Xin Han, et al.
Journal of Biomolecular Screening|August 17, 2011
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein responseAndrew M Fribley, Patricia G Cruz, Justin R Miller, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Journal of Medicinal Chemistry|July 1, 2021
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor RegressionMeng Zhang, Angelo Aguilar, Shilin Xu, et al.
Journal of Medicinal Chemistry|June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate CancerXin Han, Lijie Zhao, Weiguo Xiang, et al.
Journal of Medicinal Chemistry|September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate CancerWeiguo Xiang, Lijie Zhao, Xin Han, et al.
Journal of Biomolecular Screening|August 17, 2011
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein responseAndrew M Fribley, Patricia G Cruz, Justin R Miller, et al.
Pageof 7